Registered title, quoted from ClinicalTrials.gov
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07540390, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 65 years; sex: all
Registered eligibility fields
Pathologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or III).
Inclusion criterion 3
Stage III: TanyN3M0 / T4N0-2M0 (9th AJCC/UICC staging system).
Inclusion criterion 5
Participation in another clinical trial of an investigational drug within 3 months prior to treatment.
Exclusion criterion 4
Hemoglobin (HGB) ≥90 g/L, white blood cell count (WBC) ≥4.0×10\^9 /L, platelet count (PLT) ≥100×10\^9/L.
Inclusion criterion 7
Liver function: ALT and AST <2.5× upper limit of normal (ULN); total bilirubin <2.0×ULN.
Inclusion criterion 8
Renal function: serum creatinine <1.5×ULN.
Inclusion criterion 9
HIV-positive; HBsAg-positive with detectable HBV DNA copy number (quantitative detection ≥1000 cps/mL); positive hepatitis C antibody (HCV Ab) with detectable HCV RNA.
Exclusion criterion 10
Age 18-65 years, male or non-pregnant female.
Inclusion criterion 2
Positive pregnancy test in women of childbearing potential, or lactating women.
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: day-to-day activity level; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07540390, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntary participation and signed informed consent.
- Age 18-65 years, male or non-pregnant female.
- Pathologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or III).
- Previously untreated patients with no history of other malignancies; initial treatment for nasopharyngeal carcinoma.
- Stage III: TanyN3M0 / T4N0-2M0 (9th AJCC/UICC staging system).
- ECOG performance status 0-1, with no severe dysfunction of vital organs (heart, lung, liver, kidney, etc.).
- Hemoglobin (HGB) ≥90 g/L, white blood cell count (WBC) ≥4.0×10\^9 /L, platelet count (PLT) ≥100×10\^9/L.
- Liver function: ALT and AST <2.5× upper limit of normal (ULN); total bilirubin <2.0×ULN.
- Renal function: serum creatinine <1.5×ULN.
Exclusion Criteria:
- Patients with recurrent or distant metastatic nasopharyngeal carcinoma.
- Pathologically confirmed keratinizing squamous cell carcinoma (WHO type I).
- Receipt of systemic or topical glucocorticoid therapy within 4 weeks prior to enrollment.
- Participation in another clinical trial of an investigational drug within 3 months prior to treatment.
- Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Patients with idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans), radiation pneumonitis that is clinically symptomatic or requires steroid therapy, active pneumonitis, or other moderate-to-severe pulmonary diseases that significantly affect lung function.
- Comorbidities requiring long-term immunosuppressive medication or systemic/topical corticosteroids at immunosuppressive doses.
- Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies (or any other antibodies targeting T-cell co-stimulatory or checkpoint pathways) with documented disease progression at the time of study entry.
- Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis). Patients with vitiligo or childhood asthma that has completely resolved and requires no intervention in adulthood may be included; patients requiring bronchodilators for medical management of asthma are excluded.
- HIV-positive; HBsAg-positive with detectable HBV DNA copy number (quantitative detection ≥1000 cps/mL); positive hepatitis C antibody (HCV Ab) with detectable HCV RNA.
- Receipt of any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine) within 4 weeks prior to enrollment.
- Positive pregnancy test in women of childbearing potential, or lactating women.
- Inability to comply with scheduled follow-up due to psychological, social, family, or geographical reasons.
Quoted from ClinicalTrials.gov, NCT07540390, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07540390, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.